The Barker Lab has developed an antibody fragment called H6 that binds selectively to fibrin over soluble fibrinogen, allowing it to target wound sites where fibrinogen is polymerized into fibrin. Conjugation of H6 antibody onto the surface of ultrasoft microgels allows the microgels to bind to fibrin clots and contract the clots in platelet-like manner. Although this platelet-like particle has great therapeutic potential, they lack the capacity to brining additional clothing factors to the wound site. This ability to bring functional clotting factors to the wound site might be especially important for improving the outcome for patients with the severe bleeding disorders that have a genetic component.